|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM328478059 |
| 003 |
DE-627 |
| 005 |
20231225203014.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108803
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1094.xml
|
| 035 |
|
|
|a (DE-627)NLM328478059
|
| 035 |
|
|
|a (NLM)34302970
|
| 035 |
|
|
|a (PII)S1521-6616(21)00140-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Harada, Kaoru
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.09.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a To better understand COVID-19 infection in patients receiving biologic and immunomodulatory therapies, we evaluated prevalence and outcomes for symptomatic cases of COVID-19 at a large therapeutic infusion center in New York City during the height of the pandemic. 2074 patients received treatment with biologic infusions at our center between March and May 2020, and 34 patients developed symptomatic COVID-19 infection, for an overall low rate of 1.64%. The majority of infections and deaths were in a small subset of patients with a primary immunodeficiency. Patients with inflammatory or autoimmune conditions requiring biologic therapies tended to have mild cases. Higher inflammatory responses were observed in patients who died
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Biologic therapy
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Immunodeficiencies
|
| 650 |
|
4 |
|a Immunomodulatory therapy
|
| 650 |
|
7 |
|a Biological Factors
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 700 |
1 |
|
|a Ho, Hsi-En
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cunningham-Rundles, Charlotte
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 230(2021) vom: 01. Sept., Seite 108803
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:230
|g year:2021
|g day:01
|g month:09
|g pages:108803
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108803
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 230
|j 2021
|b 01
|c 09
|h 108803
|